DI-87

• Description :

  DI-87 is an orally active and selective deoxycytidine kinase (dCK) inhibitor with an EC50 of 10.2 nM. DI-87 has antitumor activity and is used in combination therapy against tumors expressing dCK[1].

• Product Name Alternative :

  TRE-515

• UNSPSC :

  12352005

• Target :

  DNA/RNA Synthesis

• Type :

  Reference compound

• Related Pathways :

  Cell Cycle/DNA Damage

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/di-87.html

• Purity :

  99.52

• Solubility :

  DMSO : 145 mg/mL (ultrasonic)

• Smiles :

  NC1=NC(S[C@@H](C2=C(C)SC(C3=CC=C(OC)C(OCCN4CCOCC4)=C3)=N2)C)=NC(N)=C1

• Molecular Formula :

  C23H30N6O3S2

• Molecular Weight :

  502.65

• References & Citations :

  [1]Soumya Poddar, et al. Development and Preclinical Pharmacology of a Novel dCK Inhibitor, DI-87. Biochem Pharmacol. 2020 Feb;172:113742.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• CAS Number :

  [2107280-55-5]